USPTO serial 99155128
OPTILEUKIN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 11, 2026
- Examiner
- YONTEF, DAVID ERIC
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with OPTILEUKIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Junction City, KS, US
Junction City, KS, US
Junction City, KS, US
Junction City, KS, US
Junction City, KS, US
Junction City, KS, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Dianne M. Smith-Misemer
Dianne M. Smith-Misemer HOVEY WILLIAMS LLP10801 Mastin Blvd., Suite 1000Overland Park, KS 66210United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Recombinant cytokine proteins in raw material form for scientific and medical research use; Recombinant cytokine proteins for use in manufacture of pharmaceutical products, veterinary preparations, cellular therapies, gene therapies, regenerative medicines, and vaccines; Chemicals, namely, non-animal derived cell culture media for promoting cell growth, optimization, and productivity, for scientific and research use; Non-animal derived cell culture media for promoting cell growth, optimization, and productivity, for scientific, laboratory and medical research | ACTIVE | — |
| 005 | Chemicals, namely, non-animal derived cell culture media for promoting cell growth, optimization, and productivity, for medical or veterinary purposes; Recombinant cytokine proteins for use as cell growth media for growing cells for clinical use; Recombinant cytokine proteins for use as reagents for clinical medical purposes; Recombinant cytokine protein arrays for clinical medical diagnosis purposes; Recombinant cytokine proteins sold as a component ingredient of therapeutic pharmaceuticals for the treatment of immune system related diseases and disorders; Recombinant cytokine proteins for use as reagents for medical use, for the optimization of in vitro expansion of cells; Pharmaceutical preparations, namely, cytokine drugs for the optimization of in vitro expansion of cells | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by InVitria, Inc.
- Other trademarks owned by InVitria, Inc.
- Other trademarks owned by InVitria, Inc.
- Other trademarks owned by InVitria, Inc.
- Other trademarks owned by InVitria, Inc.
- Other trademarks owned by InVitria, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Similar marks named OPTILEUKIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 11, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 11, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 20, 2026 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jul 20, 2026 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jun 25, 2026 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jun 25, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Mar 31, 2026 | IUAF | USE AMENDMENT FILED | — |
| Mar 31, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Dec 16, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 21, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 21, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 15, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 22, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 22, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 22, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 22, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 22, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 16, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 3, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 25, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 25, 2025 | NWAP | NEW APPLICATION ENTERED | — |